Eslicarbazepine is indicated as:
- Monotherapy in the treatment of partial-onset seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy;
- Adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalization.
